Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Sacituzumab Govitecan-Hziy for the Treatment of Patients with Advanced Thymoma or Thymic Carcinoma

Trial Status: active

This phase II trial tests how well sacituzumab govitecan-hziy works to treat patients with thyroma or thymic carcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP 2 receptors, and delivers govitecan to kill them.